The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas

Ovarian carcinoma is the most deadly gynecologic cancer, causing almost 15,000 deaths annually in the U.S. Most women with ovarian cancer are treated with a combination of surgery and platinum chemotherapy. Even though the majority of women respond well to this treatment initially, eventually their cancers recur and develop resistance to platinum and other types of chemotherapy. Accordingly, new treatment modalities are urgently needed for both primary and recurrent disease.